Arctoris is a global platform company headquartered in Oxford, UK that is transforming drug discovery by combining robotics and AI. Arctoris developed and operates Ulysses, a fully automated drug discovery platform. Ulysses has been created to address fundamental problems with conventional drug discovery by removing human error and variability, providing the right data at the right time to power the right decisions.
Combining a robotic platform with an experienced team, Arctoris runs integrated drug discovery projects with its partners worldwide, delivering reliable, reproducible, and fully auditable datasets enabling better decision-making early in the drug discovery process. Arctoris explains this enables leaders in biotech and pharma to take their programs from idea to Investigational New Drug (IND) and into the clinic faster.
Over the past five years, Arctoris has grown from a technology startup to a globally operating company with partners on four continents, operations in Oxford and its Asia-Pacific hub in Singapore, and a team of seasoned drug hunters and experienced engineers. Arctoris is led by its founders, Martin-Immanuel Bittner MD DPhil (CEO) and Tom Fleming MChem (COO).
Watch the video to learn how Arctoris aims to enable better data today, for better drugs tomorrow.